Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 106489

Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease


Turk, Zdenka; Šesto, Mihajlo; Skodlar, Jasna; Ferenčak, Goran; Turk, Nikša; Stavljenić-Rukavina Ana
Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease // Hormone and Metabolic Research, 34 (2002), 4; 196-201 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 106489 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease

Autori
Turk, Zdenka ; Šesto, Mihajlo ; Skodlar, Jasna ; Ferenčak, Goran ; Turk, Nikša ; Stavljenić-Rukavina Ana

Izvornik
Hormone and Metabolic Research (0018-5043) 34 (2002), 4; 196-201

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Oxidized LDL; Autoantibody; Advanced Glycation End-Products; Coronary Artery Disease; Diabetic Vascular Disease

Sažetak
Background and Aims: The oxidative modification of LDL has been shown to affect its clearance and to exert cytotoxic and immunogenic effects. The objective of our study was to analyse markers of LDL oxidation - soluble LDL containing immune complexes (LDL-ICs) in type 2 diabetes with micro- and macrovascular disease. Patients and Methods: The study included 69 diabetic patients with coronary artery disease (DM + CAD), 78 non-diabetics with CAD, 47 controls, and 27 diabetics with nephropathy and 36 free from complications. OxLDL antibodies and advanced glycated end-products were measured by ELISA, and LDL-IC apo B content after PEG precipitation. Results: Determination of a broad range of oxLDL antibody activity in all study groups showed no significant differences. In contrast, the content of apo B, a component of the antigen moiety of oxLDL-ICs, was higher in CAD and diabetes (+ CAD) than in LDL-ICs isolated from controls (p < 0.001). LDL-ICs did not differ between patients with CAD + DM and CAD patients free from diabetes. LDL-IC levels in diabetic patients with or without microangiopathy were significantly higher than in healthy volunteers (PEG-apo B 0.278 +/- 0.107 vs. 0.165 +/- 105 g/l, p < 0.002 ; PEG-IgG 151.7 +/- 76 vs. 115.4 +/- 62 g/l, p < 0.05). However, there was no significant difference in the level of circulating LDL-ICs between the subgroup of diabetic patients with nephropathy/retinopathy and patients free of microvascular disease (Ab-oxLDL 27.7 +/- 10.4 vs. 27.1 +/- 9.3 AU, NS ; PEG-apo B 0.324 +/- 0.111 vs. 0.287 +/- 0.124 g/l, NS ; PEG-IgG 1.68 +/- 0.68 vs. 1.42 +/- 0.80 g/l, NS). There was a statistically significant positive correlation between AGE content and LDL-ICs (r = 0.35, p < 0.009). A significant but inverse correlation was recorded between triglyceride concentration and level of LDL-ICs in DM + CAD (r = - 0.32, p < 0.016) and CAD patients (r = - 0.35, p < 0.002). A highly significant negative correlation between triglycerides and circulating LDL-ICs (r = - 0.54, p < 0.039) was observed in patients with early nephropathy, but not in those with physiological proteinuria. It is known that at a high triglyceride level in type 2 diabetes, the majority of LDL are small and dense, thus being more susceptible to oxidative modification. This could be a possible mechanism explaining why more LDL-ICs, with a level inversely correlating with triglyceride concentration, are generated in diabetes. Conclusion: The increased level of circulating LDL-ICs is a risk factor for the general population, including those with diabetes. Our results suggested the contribution of LDL-ICs to the development of atherosclerosis to probably be more significant than the direct contribution of oxLDLAb itself.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekti:
0045003

Ustanove:
Klinika za dijabetes, endokrinologiju i bolesti metabolizma Vuk Vrhovac

Profili:

Avatar Url Zdenka Turk (autor)

Avatar Url Goran Ferenčak (autor)

Avatar Url Nikša Turk (autor)

Avatar Url Ana Stavljenić (autor)

Avatar Url Mihajlo Šesto (autor)

Avatar Url Jasna Mesarić (autor)


Citiraj ovu publikaciju:

Turk, Zdenka; Šesto, Mihajlo; Skodlar, Jasna; Ferenčak, Goran; Turk, Nikša; Stavljenić-Rukavina Ana
Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease // Hormone and Metabolic Research, 34 (2002), 4; 196-201 (međunarodna recenzija, članak, znanstveni)
Turk, Z., Šesto, M., Skodlar, J., Ferenčak, G., Turk, N. & Stavljenić-Rukavina Ana (2002) Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease. Hormone and Metabolic Research, 34 (4), 196-201.
@article{article, author = {Turk, Zdenka and \v{S}esto, Mihajlo and Skodlar, Jasna and Feren\v{c}ak, Goran and Turk, Nik\v{s}a}, year = {2002}, pages = {196-201}, keywords = {Oxidized LDL, Autoantibody, Advanced Glycation End-Products, Coronary Artery Disease, Diabetic Vascular Disease}, journal = {Hormone and Metabolic Research}, volume = {34}, number = {4}, issn = {0018-5043}, title = {Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease}, keyword = {Oxidized LDL, Autoantibody, Advanced Glycation End-Products, Coronary Artery Disease, Diabetic Vascular Disease} }
@article{article, author = {Turk, Zdenka and \v{S}esto, Mihajlo and Skodlar, Jasna and Feren\v{c}ak, Goran and Turk, Nik\v{s}a}, year = {2002}, pages = {196-201}, keywords = {Oxidized LDL, Autoantibody, Advanced Glycation End-Products, Coronary Artery Disease, Diabetic Vascular Disease}, journal = {Hormone and Metabolic Research}, volume = {34}, number = {4}, issn = {0018-5043}, title = {Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease}, keyword = {Oxidized LDL, Autoantibody, Advanced Glycation End-Products, Coronary Artery Disease, Diabetic Vascular Disease} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka::


  • Excerpta Medica
  • Index Medicus





Contrast
Increase Font
Decrease Font
Dyslexic Font